share_log

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $17

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $17

查丹資本維持對Sonnet BioTherapeutics的買入,將目標股價下調至17美元
Benzinga ·  2023/04/19 06:23

Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and lowers the price target from $22 to $17.

Chardan Capital分析師Keay Nakae維持Sonnet BioTherapeutics(納斯達克股票代碼:SONN)的買入,並將目標股價從22美元下調至17美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論